PERCEPTIVE ADVISORS LLC (CIK 1224962) reported 25 SEC Form 4 insider transactions across 8 companies over the past 18 months (most recent 2026-04-23). Recent activity: Buy MGTX (555,555 shares), Sell MGTX (2.3M shares), Buy ATHA (989,270 shares), Buy ATHA (329,756 shares), Sell LYRA (4,783 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-23 | MeiraGTx Holdings plc (MGTX) | Director | Buy | 555,555 | $5.0M |
| 2026-01-02 | MeiraGTx Holdings plc (MGTX) | Director | Sell | 2.3M | $18.2M |
| 2025-12-23 | Athira Pharma, Inc. (ATHA) | Director | Buy | 989,270 | $6.3M |
| 2025-12-23 | Athira Pharma, Inc. (ATHA) | Director | Buy | 329,756 | $2.1M |
| 2025-11-13 | Lyra Therapeutics, Inc. (LYRA) | Insider | Sell | 4,783 | $20,615 |
| 2025-11-13 | Lyra Therapeutics, Inc. (LYRA) | Insider | Sell | 537 | $2,314 |
| 2025-11-13 | Lyra Therapeutics, Inc. (LYRA) | Insider | Sell | 7,862 | $31,920 |
| 2025-11-13 | Lyra Therapeutics, Inc. (LYRA) | Insider | Sell | 883 | $3,585 |
| 2025-11-13 | Lyra Therapeutics, Inc. (LYRA) | Insider | Sell | 28,597 | $111,528 |
| 2025-11-13 | Lyra Therapeutics, Inc. (LYRA) | Insider | Sell | 3,213 | $12,531 |
| 2025-11-10 | Lyra Therapeutics, Inc. (LYRA) | Insider | Sell | 17,746 | $84,294 |
| 2025-11-10 | Lyra Therapeutics, Inc. (LYRA) | Insider | Sell | 3,247 | $16,819 |
| 2025-11-10 | Lyra Therapeutics, Inc. (LYRA) | Insider | Sell | 28,902 | $149,712 |
| 2025-11-10 | Lyra Therapeutics, Inc. (LYRA) | Insider | Sell | 1,993 | $9,467 |
| 2025-11-10 | Lyra Therapeutics, Inc. (LYRA) | Insider | Sell | 16,633 | $75,514 |
| 2025-11-10 | Lyra Therapeutics, Inc. (LYRA) | Insider | Sell | 1,869 | $8,485 |
| 2025-08-05 | Orchestra BioMed Holdings, Inc. (OBIO) | Insider | Buy | 700,000 | $1.9M |
| 2025-05-01 | Acrivon Therapeutics, Inc. (ACRV) | Insider | Sell | 437,881 | $617,412 |
| 2025-05-01 | Acrivon Therapeutics, Inc. (ACRV) | Insider | Sell | 298,886 | $400,507 |
| 2025-04-29 | Acrivon Therapeutics, Inc. (ACRV) | Insider | Sell | 1.1M | $2.1M |
| 2025-04-29 | Acrivon Therapeutics, Inc. (ACRV) | Insider | Sell | 215,283 | $335,841 |
| 2025-04-29 | Acrivon Therapeutics, Inc. (ACRV) | Insider | Sell | 250,000 | $352,500 |
| 2025-04-07 | Aldeyra Therapeutics, Inc. (ALDX) | Insider | Sell | 3.4M | $4.8M |
| 2025-02-21 | Solid Biosciences Inc. (SLDB) | Director | Buy | 5.0M | $20.1M |
| 2025-02-14 | Adagio Medical Holdings, Inc. (ADGM) | Director | Buy | 64,167 | $0 |
Source: SEC Form 4 filings · as of 2026-04-23